Literature DB >> 7538656

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

M Alimandi1, A Romano, M C Curia, R Muraro, P Fedi, S A Aaronson, P P Di Fiore, M H Kraus.   

Abstract

In the present study we demonstrate that erbB-3 and erbB-2 cooperate in neoplastic transformation. Under conditions in which neither gene alone induced transformation, they readily transformed NIH3T3 cells if co-expressed. Furthermore, at high expression levels of ErbB2 which cause transformation, ErbB3 enhanced focus formation by one order of magnitude. Synergy required an intact ErbB2 extracellular domain and tyrosine kinase activity. Cooperation between ErbB3 and ErbB2 involved heterodimerization and increased tyrosine phosphorylation of ErbB3. Signaling by the heterodimer resulted in increased PI 3-kinase recruitment as well as quantitative and qualitative differences in substrate phosphorylation. Evidence for signaling by an active ErbB3-ErbB2 heterodimer in four mammary tumor cell lines indicated relevance of this mechanism for human neoplasia. Our detection of the NDF/heregulin transcript in NIH3T3 cells implicates an autocrine loop involving this ligand in signaling by the ErbB3-ErbB2 heterodimer in the model system, whereas heregulin-independent mechanisms likely exist for cooperative signaling by ErbB3 and ErbB2 chronically activated in some human mammary carcinomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538656

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  176 in total

1.  The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

Authors:  H Waterman; I Alroy; S Strano; R Seger; Y Yarden
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Positive and negative regulation of endogenous genes by designed transcription factors.

Authors:  R R Beerli; B Dreier; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 3.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 4.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 5.  ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

Authors:  R Pinkas-Kramarski; I Alroy; Y Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

6.  ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Authors:  D Graus-Porta; R R Beerli; J M Daly; N E Hynes
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

7.  Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation.

Authors:  Rosana D Meyer; Amrik Singh; Fredric Majnoun; Catharina Latz; Kameran Lashkari; Nader Rahimi
Journal:  Oncogene       Date:  2004-07-15       Impact factor: 9.867

Review 8.  Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.

Authors:  Brent N Rexer; Carlos L Arteaga
Journal:  Crit Rev Oncog       Date:  2012

Review 9.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

Review 10.  Molecular pathways: HER3 targeted therapy.

Authors:  Kinisha Gala; Sarat Chandarlapaty
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.